share_log

三葉草生物-B：自願公告 - 三葉草生物公佈針對腫瘤化療相關性血小板減少症(CIT) 的靶向藥物SCB-219M I期臨床試驗的積極數據

CLOVER BIO-B: VOLUNTARY ANNOUNCEMENT - CLOVER ANNOUNCES POSITIVE PHASE I RESULTS FOR SCB-219M FOR TREATMENT OF CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

香港交易所 ·  Dec 28, 2023 18:00
Summary by Moomoo AI
三葉草生物製藥有限公司（「三葉草生物」）於2023年12月29日宣佈，其開發的針對腫瘤化療相關性血小板減少症（CIT）的靶向藥物SCB-219M，在I期臨床試驗中獲得積極數據。該試驗是一項多中心、開放性、劑量爬坡和劑量擴增研究，旨在探索SCB-219M經皮下註射在CIT患者中的安全性、耐受性、免疫原性及藥物動力學特性。初步結果顯示，所有接受該藥物治療的腫瘤患者（共9例）在一周後血小板計數均能保持或恢復至安全水平，且療效至少持續三周。此外，SCB-219M展現了良好的安全性和耐受性，未觀察到任何嚴重不良事件或劑量限制性毒性。三葉草生物計劃於2024年啟動Ib期臨床試驗，進一步評估SCB-219M在CIT和CTIT患者中的療效。CIT是一種常見於腫瘤患者的嚴重化療並發症，可能導致治療延遲或劑量減少，以及潛在的致命性出血。公司呼籲股東及潛在投資者於買賣股份時應審慎行事。
三葉草生物製藥有限公司（「三葉草生物」）於2023年12月29日宣佈，其開發的針對腫瘤化療相關性血小板減少症（CIT）的靶向藥物SCB-219M，在I期臨床試驗中獲得積極數據。該試驗是一項多中心、開放性、劑量爬坡和劑量擴增研究，旨在探索SCB-219M經皮下註射在CIT患者中的安全性、耐受性、免疫原性及藥物動力學特性。初步結果顯示，所有接受該藥物治療的腫瘤患者（共9例）在一周後血小板計數均能保持或恢復至安全水平，且療效至少持續三周。此外，SCB-219M展現了良好的安全性和耐受性，未觀察到任何嚴重不良事件或劑量限制性毒性。三葉草生物計劃於2024年啟動Ib期臨床試驗，進一步評估SCB-219M在CIT和CTIT患者中的療效。CIT是一種常見於腫瘤患者的嚴重化療並發症，可能導致治療延遲或劑量減少，以及潛在的致命性出血。公司呼籲股東及潛在投資者於買賣股份時應審慎行事。
Clover Biopharmaceuticals Limited (“Clover Biologics”) announced on December 29, 2023 that its development of SCB-219M, a targeted drug for tumor chemotherapy-associated thrombocytopenia (CIT), received positive data in a Phase I clinical trial. The trial is a multi-center, open-label, dose-climbing, and dose-escalation study to explore the safety, tolerability, immunogenicity, and pharmacokinetic properties of SCB-219M injected subcutaneously in patients with CIT. Preliminary results showed that all cancer patients treated with the drug (a total of 9 cases) maintained or restored platelet counts after one week, and efficacy lasted for at least three weeks. In addition, SCB-219M demonstrated good safety and tolerability, with no serious adverse events or dose-limiting toxicity observed. Clover Biologics plans to launch Phase Ib clinical trials...Show More
Clover Biopharmaceuticals Limited (“Clover Biologics”) announced on December 29, 2023 that its development of SCB-219M, a targeted drug for tumor chemotherapy-associated thrombocytopenia (CIT), received positive data in a Phase I clinical trial. The trial is a multi-center, open-label, dose-climbing, and dose-escalation study to explore the safety, tolerability, immunogenicity, and pharmacokinetic properties of SCB-219M injected subcutaneously in patients with CIT. Preliminary results showed that all cancer patients treated with the drug (a total of 9 cases) maintained or restored platelet counts after one week, and efficacy lasted for at least three weeks. In addition, SCB-219M demonstrated good safety and tolerability, with no serious adverse events or dose-limiting toxicity observed. Clover Biologics plans to launch Phase Ib clinical trials in 2024 to further evaluate the efficacy of SCB-219M in CIT and CTIT patients. CIT IS A SEVERE CHEMOTHERAPY COMPLICATION COMMON IN PATIENTS WITH TUMORS THAT MAY RESULT IN DELAYED TREATMENT OR REDUCED DOSES, AS WELL AS POTENTIALLY FATAL BLEEDING. The Company urges shareholders and potential investors to exercise caution when trading shares.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more